Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238796 | 1.00 | HTR6 (0.48) | HTR6SMN1; SMN2 | |
| SCHEMBL337751 | 1.00 | HTR6 (0.48) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1190497 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL311292 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20528061 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3649582 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2033780 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1726824 | 0.98 | HTR6 (0.47) | HTR6SMN1; SMN2 | |
| SCHEMBL18091509 | 0.82 | HTR6 (0.57) | HTR6SMN1; SMN2 | |
| SCHEMBL19990312 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-5191079-A | Chemical intermediates for bactericides | KANEBO, LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| US-5166203-A | QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME | KANEBO, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0472826-A2 | Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound | KANEBO LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HTR6 3197/4885SMN1; SMN2 564/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | HTR6 3197/4885SMN1; SMN2 564/4885 |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | NRAS, KRAS, HRAS | HTR6 3642/4885SMN1; SMN2 1533/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | HTR6 3406/4885SMN1; SMN2 390/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HTR6 2732/4885SMN1; SMN2 301/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | HTR6 2314/4885SMN1; SMN2 2937/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | HTR6 51/4885SMN1; SMN2 2635/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | HTR6 661/4885SMN1; SMN2 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.